STimulation to Activate RespIration

Last updated: May 13, 2025
Sponsor: Lungpacer Medical Inc.
Overall Status: Active - Recruiting

Phase

2

Condition

N/A

Treatment

Phrenic Nerve Stimulation

Clinical Study ID

NCT06832306
P-600
75A0123C00021
  • Ages > 18
  • All Genders

Study Summary

Multi-center, randomized, controlled, open-label Phase 2 feasibility trial. Subjects on mechanical ventilation (MV) for acute hypoxemic respiratory failure (AHRF) with lung injury (including subjects who meet criteria for acute respiratory distress syndrome (ARDS)) will be randomized 2:1 to diaphragm neurostimulation-assisted ventilation (DNAV) using the AeroNova System plus lung-protective ventilation (Treatment) vs. lung-protective ventilation alone (Control).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Male or female, 18 years or older, and

  2. Able to provide informed consent or have a legally authorized representative (LAR) /Substitute Decision Maker (SDM) who can provide consent, and

  3. Have acute onset of new respiratory symptoms or dysfunction within the 2 weeksbefore onset of need for respiratory support, and

  4. Have moderate-to-severe arterial hypoxemia defined by one of:

  • PaO2:FiO2 ratio <≤200 mm Hg on PEEP ≥ 5 cm H2O, or

  • In the absence of an available arterial blood gas, SpO2 ≤97% on FiO2 ≥0.5 andPEEP ≥5 cm H2O with reliable SpO2 trace for the 2 hours immediately precedingeligibility assessment (this correlates to an upper limit of SpO2:FiO2 ratio of 235%) or

  • Are receiving inhaled nitric oxide for acute hypoxemia, or

  • Are being ventilated in the prone position for acute hypoxemia, and

  1. Have been mechanically ventilated for AHRF in the current ICU for <72 hours at thetime of enrolment, and

  2. Are expected to require invasive mechanical ventilation ≥ 48 hours after enrollmentin the opinion of the treating clinician, and

  3. Have not spontaneously triggered the ventilator for the previous 2 hours and thereis no immediate plan to transition to assisted ventilation.

Exclusion

Exclusion Criteria:

  1. Hypoxemia is primarily attributable to acute exacerbation of chronic obstructivepulmonary disease, status asthmaticus, or pulmonary embolism.

  2. Underlying chronic parenchymal lung disease that may make recovery/extubation achallenge (e.g., COPD, pulmonary fibrosis).

  3. Broncho-pleural fistula at the time of eligibility assessment.

  4. Severe hemodynamic instability (requiring norepinephrine or epinephrine > 0.5mcg/kg/min)

  5. Require extracorporeal membrane oxygenation.

  6. Pre-existing neurological, neuromuscular or muscular disorder or known phrenic nerveinjury that could affect the respiratory muscles.

  7. BMI >70 kg/m2.

  8. Contraindications to left internal jugular vein or left subclavian veincatheterization (e.g., infection at the access site, known central venous stenosis,septic thrombophlebitis, left internal jugular ECMO cannula in situ, poor targetvessels).

  9. Patient expected to transition to fully palliative care within 72 hours ofenrollment.

  10. Severe liver disease (Child-Pugh Score ≥10)

  11. Treating clinician deems enrollment not clinically appropriate.

  12. Currently enrolled in any other study of an investigational drug or device, whichmay affect the outcomes of the current study.

  13. Any electrical device (implanted or external) that may be prone to interaction withor interference from the AeroNova System, including neurological pacing/stimulatordevices and cardiac pacemakers and defibrillators.

  14. Known or suspected to be pregnant or lactating.

Study Design

Total Participants: 30
Treatment Group(s): 1
Primary Treatment: Phrenic Nerve Stimulation
Phase: 2
Study Start date:
February 28, 2025
Estimated Completion Date:
December 31, 2026

Connect with a study center

  • Toronto General Hospital

    Toronto, Ontario M5G 2C4
    Canada

    Site Not Available

  • University Health Network (UHN)

    Toronto, Ontario M5G 2C4
    Canada

    Active - Recruiting

  • Louisiana State University Health Sciences

    Shreveport, Louisiana 71103
    United States

    Active - Recruiting

  • Prisma Health

    Columbia, South Carolina 29203
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.